colipase like 2Genealiases: AAAL3045 · C6orf126 · UNQ3045 · dJ510O8.5
Q-omics provides the consensus-scored CLPSL2 profile across patient tissues and cancer cell-line models. CLPSL2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CLPSL2 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, CLPSL2 RNA expression shows 11,931 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, LUAD, and TGCT as cancer lineages where CLPSL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLPSL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLPSL2 survival associations across molecular data types. CLPSL2 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLPSL2 RNA expression–survival associations across cancer types. High CLPSL2 expression shows unfavorable associations in UVM, KIRC, COAD, SKCM and CHOL, but favorable associations in OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CLPSL2 RNA expression.
This table summarizes CLPSL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CLPSL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLPSL2 shows higher tumor expression in LUAD, THCA, COAD, KIRP, BLCA and BRCA. The LUAD box plot shows higher CLPSL2 RNA expression in tumor versus normal tissue (log2 FC = +1.420, t-test p < 0.001).
This table shows molecular features associated with CLPSL2 in patient tissues and cancer cell lines. In patient samples, CLPSL2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CLPSL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LUNG_SCLC.
